Walleye Capital LLC Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Walleye Capital LLC bought a new position in Arcus Biosciences, Inc. (NYSE:RCUS) during the third quarter, Holdings Channel reports. The firm bought 238,544 shares of the company’s stock, valued at approximately $3,647,000.

Other hedge funds also recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Arcus Biosciences by 6.9% during the 3rd quarter. FMR LLC now owns 4,467,557 shares of the company’s stock worth $68,309,000 after acquiring an additional 286,766 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after purchasing an additional 186,750 shares in the last quarter. SG Americas Securities LLC lifted its position in Arcus Biosciences by 1,396.1% during the second quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock valued at $1,969,000 after purchasing an additional 120,650 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Arcus Biosciences by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 4,791,244 shares of the company’s stock worth $90,459,000 after buying an additional 110,528 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Arcus Biosciences in the 2nd quarter worth about $1,286,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RCUS has been the subject of a number of analyst reports. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Barclays boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $15.94 on Tuesday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock’s fifty day moving average is $16.24 and its two-hundred day moving average is $16.02. Arcus Biosciences, Inc. has a 52 week low of $13.52 and a 52 week high of $20.31. The company has a market capitalization of $1.46 billion, a PE ratio of -4.90 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $48.00 million for the quarter, compared to analysts’ expectations of $38.95 million. During the same period in the prior year, the business posted ($0.94) earnings per share. The business’s revenue for the quarter was up 50.0% on a year-over-year basis. As a group, analysts expect that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.